Eclipse BioInnovations is Discovery Tools (Healthcare) in United States that focus on Ribonucleic acid business. Founded in 2017. They cover business area such as developer, cell-free genomics technology, specialized genomics-base product, service, a method, immunoprecipitation, assist, RNA, (Ribonucleic acid, bind protein target, scientist, academic customer, new and effective drug, human disease.
2017
( 7 years old in 2024 )
Ribonucleic Acid
-
6195 Cornerstone Court East
Suite 105
San Diego, CA 92121
United States
Private
developercell-free genomics technologyspecialized genomics-base productservicea methodimmunoprecipitationassistRNA(Ribonucleic acidbind protein targetscientistacademic customernew and effective drughuman disease
* We use standard office opening hours in near Eclipse BioInnovations's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
Eclipse BioInnovations is Discovery Tools (Healthcare) business from United States that founded in 2017 (7 years old in 2024), Eclipse BioInnovations business is focusing on Ribonucleic Acid.
Eclipse BioInnovations headquarter office and corporate office address is located in 6195 Cornerstone Court East Suite 105 San Diego, CA 92121 United States.
Eclipse BioInnovations was founded in United States.
In 2024, Eclipse BioInnovations is currently focus on Ribonucleic acid sector.
Above is snippet of Google Trends for "Ribonucleic acid" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with Eclipse BioInnovations, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
